Literature DB >> 17021169

Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation.

Holly Oakley1, Sarah L Cole, Sreemathi Logan, Erika Maus, Pei Shao, Jeffery Craft, Angela Guillozet-Bongaarts, Masuo Ohno, John Disterhoft, Linda Van Eldik, Robert Berry, Robert Vassar.   

Abstract

Mutations in the genes for amyloid precursor protein (APP) and presenilins (PS1, PS2) increase production of beta-amyloid 42 (Abeta42) and cause familial Alzheimer's disease (FAD). Transgenic mice that express FAD mutant APP and PS1 overproduce Abeta42 and exhibit amyloid plaque pathology similar to that found in AD, but most transgenic models develop plaques slowly. To accelerate plaque development and investigate the effects of very high cerebral Abeta42 levels, we generated APP/PS1 double transgenic mice that coexpress five FAD mutations (5XFAD mice) and additively increase Abeta42 production. 5XFAD mice generate Abeta42 almost exclusively and rapidly accumulate massive cerebral Abeta42 levels. Amyloid deposition (and gliosis) begins at 2 months and reaches a very large burden, especially in subiculum and deep cortical layers. Intraneuronal Abeta42 accumulates in 5XFAD brain starting at 1.5 months of age (before plaques form), is aggregated (as determined by thioflavin S staining), and occurs within neuron soma and neurites. Some amyloid deposits originate within morphologically abnormal neuron soma that contain intraneuronal Abeta. Synaptic markers synaptophysin, syntaxin, and postsynaptic density-95 decrease with age in 5XFAD brain, and large pyramidal neurons in cortical layer 5 and subiculum are lost. In addition, levels of the activation subunit of cyclin-dependent kinase 5, p25, are elevated significantly at 9 months in 5XFAD brain, although an upward trend is observed by 3 months of age, before significant neurodegeneration or neuron loss. Finally, 5XFAD mice have impaired memory in the Y-maze. Thus, 5XFAD mice rapidly recapitulate major features of AD amyloid pathology and may be useful models of intraneuronal Abeta42-induced neurodegeneration and amyloid plaque formation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021169      PMCID: PMC6674618          DOI: 10.1523/JNEUROSCI.1202-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  59 in total

Review 1.  Function and dysfunction of the presenilins.

Authors:  S S Sisodia; S H Kim; G Thinakaran
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

2.  Intraneuronal Abeta42 accumulation in human brain.

Authors:  G K Gouras; J Tsai; J Naslund; B Vincent; M Edgar; F Checler; J P Greenfield; V Haroutunian; J D Buxbaum; H Xu; P Greengard; N R Relkin
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

Review 3.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

4.  Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences.

Authors:  J T Rogers; L M Leiter; J McPhee; C M Cahill; S S Zhan; H Potter; L N Nilsson
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

5.  Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain.

Authors:  D Moechars; I Dewachter; K Lorent; D Reversé; V Baekelandt; A Naidu; I Tesseur; K Spittaels; C V Haute; F Checler; E Godaux; B Cordell; F Van Leuven
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

Review 6.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

7.  Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease.

Authors:  M R D'Andrea; R G Nagele; H Y Wang; P A Peterson; D H Lee
Journal:  Histopathology       Date:  2001-02       Impact factor: 5.087

8.  Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome.

Authors:  K A Gyure; R Durham; W F Stewart; J E Smialek; J C Troncoso
Journal:  Arch Pathol Lab Med       Date:  2001-04       Impact factor: 5.534

9.  Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP.

Authors:  G Feng; R H Mellor; M Bernstein; C Keller-Peck; Q T Nguyen; M Wallace; J M Nerbonne; J W Lichtman; J R Sanes
Journal:  Neuron       Date:  2000-10       Impact factor: 17.173

Review 10.  Genetics of Alzheimer's disease.

Authors:  M Hutton; J Pérez-Tur; J Hardy
Journal:  Essays Biochem       Date:  1998       Impact factor: 8.000

View more
  1119 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

2.  5XFAD mice show early-onset gap encoding deficits in the auditory cortex.

Authors:  Aldis P Weible; Amanda J Stebritz; Michael Wehr
Journal:  Neurobiol Aging       Date:  2020-06-01       Impact factor: 4.673

Review 3.  Alzheimer's Disease: The Link Between Amyloid-β and Neurovascular Dysfunction.

Authors:  Ernesto Solis; Kevin N Hascup; Erin R Hascup
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

4.  Upregulation of Alzheimer's Disease Amyloid-β Protein Precursor in Astrocytes Both in vitro and in vivo.

Authors:  Yingxia Liang; Frank Raven; Joseph F Ward; Sherri Zhen; Siyi Zhang; Haoqi Sun; Sean J Miller; Se Hoon Choi; Rudolph E Tanzi; Can Zhang
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer's disease.

Authors:  Charles Y Shao; Suzanne S Mirra; Hameetha B R Sait; Todd C Sacktor; Einar M Sigurdsson
Journal:  Acta Neuropathol       Date:  2011-06-01       Impact factor: 17.088

Review 6.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

7.  Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice.

Authors:  Latha Devi; Masuo Ohno
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

8.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

Review 9.  Sphingolipid-Enriched Extracellular Vesicles and Alzheimer's Disease: A Decade of Research.

Authors:  Michael B Dinkins; Guanghu Wang; Erhard Bieberich
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Profiling of Differential Expression of Genes in Mice Carrying Both Mutant Presenilin 1 and Amyloid Precursor Protein Transgenes with or without Knockout of B2 Adrenergic Receptor Gene.

Authors:  Yuan Zhou; Lintao Chen; Xi Zhou; Yechun Pei; Shuangshuang Wei; Anum Mehmood; Yang K Xiang; Dayong Wang
Journal:  J Appl Bioinforma Comput Biol       Date:  2018-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.